Revive Therapeutics Ltd. (CSE: RVV) (OTCMKTS: RVVTF) CEO Michael Frank and Psilocin Pharma Founder Derrick Welsh explain to Proactive how the Toronto-based company is currently advancing to a Phase 3 clinical trial to treat the coronavirus with a rheumatoid arthritis therapy, in addition to its efforts to advance its oral dosage forms of psilocybin.
Psilocybin is the chemical found in magic mushrooms, which may be used to treat a variety of diseases and disorders.
Welsh says psilocybin has the potential to be as popular as cannabis in the biopharma space.